Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8183207B2 · kind B2 · utility
22Cited by
5References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 25, 2009 |
| Grant date | May 22, 2012 |
| Priority date | — |
| Expiry date | Dec 22, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of using colony stimulating factor receptor (CSF1R) extracellular domain (ECD) fusion molecules for treating osteolytic bone loss, cancer metastasis, cancer metastasis-induced osteolytic bone loss, and tumor growth are provided. CSF1R ECD fusion molecules, polynucleotides encoding CSF1R ECD fusion molecules, and methods of making CSF1R ECD fusion molecules are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.